Any questions or requests for more information may be directed to Cereno’s Management Team, or directly to the CEO Sten R Sörensen:

Phone: +46 (0) 733 74 03 74


Interim report Q1 24 May 2017

Interim report Q2 & H1 23 August 2017

Interim report Q3 14 November 2017

Cereno Scientific

(Video in Swedish) Cereno Scientific is developing a new preventive drug that normalizes the body’s own defence system against blood clots - to be used on the global market for the treatment of complications resulting from thrombosis-related cardiovascular diseases.

About Cereno Scientific